Chronic lymphocytic leukemia and prolymphocytic leukemia. Two coins or two sides of the same coin?

Laura Magnano,[1,2] Alba Navarro,[2,3*] Mónica López-Guerra,[1,2,3] Guillem Clot,[2,3] Sílvia Beà,[1,2,3] Gabriela Bastidas,[4] Dolors Costa,[1,2,3] Andrea Rivero,[4] Marta Garrote,[4] Eva Giné,[2,3,4] María Rozman,[1,2,3] Marta Aymerich,[1,2,3] Dolors Colomer,[1,2,3] Armando López-Guillermo,[2,3,4] Elías Campo,[1,2,3] Neus Villamor[1,2,3] and Estella Matutes[1]*

**LM and AN contributed equally as co-first authors*

[1]Hemathopatology Unit, Department of Pathology, Hospital Clínic of Barcelona; [2]Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); [3]Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) and [4]Hematology Department, Hospital Clínic of Barcelona, Barcelona, Spain

Correspondence: LAURA MAGNANO - lcmagnan@clinic.cat

doi:10.3324/haematol.2020.253062

Supplementary table.

	B-PLL	CLL	B-PLL + CLL
Morphology	Medium to large sized lymphoid cells with a round nucleus, prominent single nucleolus, and moderately basophilic cytoplasm	Lymphocytes with clumped chromatin and smudge cells	Mixture of prolymphocytes and CLL cells
Immunophenotype	B-lymphocytes lambda+, $CD5^{+}$, $FMC7^{++}$, $CD10^{-}$, $CD23^{-}$ $CD200^{-}$ and $CD43^{-}$. The antigen intensity of CD20, CD22 and CD79b was normal	B-lymphocytes $CD5^{+}$, $CD23^{+}$, $CD43^{+}$, $CD200^{+}$, $CD10^{-}$, CD20 and CD22 weakly positive and weak kappa light chain restriction	Three populations: 1. CLL phenotype with kappa light chain restriction 2. Phenotype of the B-PLL cells with lambda light chain restriction 3. Polytypic B-cell phenotype
Fluorescence *in situ* hybridization (FISH)	*MYC* (8q24) rearrangement *BCL6*, *BCL2*, *CCND1* and *CCND2* were not rearranged *TP53* was not deleted. The t(11;14)(q13;q32) was absent	*MYC* (8q24) rearrangement was not detected *ATM*, *D12Z3*, *DLEU*, *LAMP1* and *TP53* was normal.	--
Molecular analysis	*CCND1, SOX11, HDGFRP3, DBN1, CCND2, CCDN3,FMOD, KSR2, MYOF, MME, CXCR, and CAMSAP2* were not overexpressed No mutations in *TP53* or in hotspot regions of *BRAF, MYD88, NOTCH2, NOTCH1*, and *MAP2K1*	--	--
Sequencing study	IGHV5-51 family	IGHV1-69 family	IGHV5-51 family IGHV1-69 family